UPLIZNA

This brand name is authorized in Estonia, Japan, United States

Active ingredients

The drug UPLIZNA contains one active pharmaceutical ingredient (API):

1 Inebilizumab
UNII 74T7185BMM - INEBILIZUMAB

Inebilizumab is a CD19-directed humanized afucosylated IgG1 monoclonal antibody produced by recombinant DNA technology. The precise mechanism by which inebilizumab exerts its therapeutic effects in neuromyelitis optica spectrum disorder (NMOSD) is unknown but is presumed to involve binding to CD19, a cell surface antigen presents on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, inebilizumab-cdon results in antibody-dependent cellular cytolysis.

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
UPLIZNA Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L04AG10 L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AG Monoclonal antibodies
Discover more medicines within L04AG10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1836547, 1881806
Country: JP 医薬品医療機器総合機構 Identifier(s): 6399429A1026
Country: US FDA, National Drug Code Identifier(s): 72677-551

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.